INDIVIOR PHARMACEUTICALS INC (INDV) Fundamental Analysis & Valuation

NASDAQ:INDV • US45579U1097

Current stock price

30.5 USD
-0.03 (-0.1%)
At close:
30.45 USD
-0.05 (-0.16%)
Pre-Market:

This INDV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. INDV Profitability Analysis

1.1 Basic Checks

  • INDV had positive earnings in the past year.
  • In the past year INDV had a positive cash flow from operations.
  • In multiple years INDV reported negative net income over the last 5 years.
  • In multiple years INDV reported negative operating cash flow during the last 5 years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • INDV has a better Return On Assets (8.62%) than 89.58% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 50.62%, INDV belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for INDV is significantly above the industry average of 12.98%.
  • The 3 year average ROIC (43.06%) for INDV is below the current ROIC(50.62%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • INDV has a Profit Margin of 10.34%. This is amongst the best in the industry. INDV outperforms 84.90% of its industry peers.
  • INDV's Profit Margin has declined in the last couple of years.
  • INDV has a Operating Margin of 24.49%. This is amongst the best in the industry. INDV outperforms 92.19% of its industry peers.
  • In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 85.51%, INDV belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
  • In the last couple of years the Gross Margin of INDV has remained more or less at the same level.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

4

2. INDV Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INDV is creating value.
  • There is no outstanding debt for INDV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • INDV has an Altman-Z score of 2.54. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • INDV has a Altman-Z score of 2.54. This is in the better half of the industry: INDV outperforms 66.67% of its industry peers.
  • The Debt to FCF ratio of INDV is 2.68, which is a good value as it means it would take INDV, 2.68 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 2.68, INDV belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.54
ROIC/WACC5.25
WACC9.65%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a Current ratio of 0.96. This is amonst the worse of the industry: INDV underperforms 84.38% of its industry peers.
  • A Quick Ratio of 0.79 indicates that INDV may have some problems paying its short term obligations.
  • The Quick ratio of INDV (0.79) is worse than 81.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2

3. INDV Growth Analysis

3.1 Past

  • INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 459.09%, which is quite impressive.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

  • INDV is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.07% yearly.
  • The Revenue is expected to grow by 0.79% on average over the next years.
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue Next Year-2.8%
Revenue Next 2Y1.11%
Revenue Next 3Y1.73%
Revenue Next 5Y0.79%

3.3 Evolution

INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

8

4. INDV Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.40, INDV is valued correctly.
  • Based on the Price/Earnings ratio, INDV is valued cheaply inside the industry as 88.02% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.73, INDV is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 9.90, the valuation of INDV can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, INDV is valued cheaply inside the industry as 88.54% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of INDV to the average of the S&P500 Index (23.72), we can say INDV is valued rather cheaply.
Industry RankSector Rank
PE 12.4
Fwd PE 9.9
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • INDV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INDV is cheaper than 85.42% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 80.73% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 31.79
EV/EBITDA 11.72
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • INDV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of INDV may justify a higher PE ratio.
  • A more expensive valuation may be justified as INDV's earnings are expected to grow with 13.27% in the coming years.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y13.27%

0

5. INDV Dividend Analysis

5.1 Amount

  • No dividends for INDV!.
Industry RankSector Rank
Dividend Yield 0%

INDV Fundamentals: All Metrics, Ratios and Statistics

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (3/19/2026, 8:08:00 PM)

Premarket: 30.45 -0.05 (-0.16%)

30.5

-0.03 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-22
Inst Owners86.43%
Inst Owner Change-70.46%
Ins Owners3.62%
Ins Owner Change39.53%
Market Cap3.81B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (52.39%)
Short Float %8.33%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.86%
EPS NY rev (3m)3.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.17%
Valuation
Industry RankSector Rank
PE 12.4
Fwd PE 9.9
P/S 3.23
P/FCF 31.79
P/OCF 21.19
P/B N/A
P/tB N/A
EV/EBITDA 11.72
EPS(TTM)2.46
EY8.07%
EPS(NY)3.08
Fwd EY10.1%
FCF(TTM)0.96
FCFY3.15%
OCF(TTM)1.44
OCFY4.72%
SpS9.43
BVpS-1.66
TBVpS-1.67
PEG (NY)0.49
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.54
F-Score8
WACC9.65%
ROIC/WACC5.25
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-2.8%
Revenue Next 2Y1.11%
Revenue Next 3Y1.73%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1051.87%
EBIT Next 3Y148.64%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV Fundamental Analysis FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


What is the profitability of INDV stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


How financially healthy is INDIVIOR PHARMACEUTICALS INC?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?

The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.